Evidence map›Paper›PMID 37488181›Full record

ArticleScientific reports2023

Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.

Toshihiko Matsumoto, Tatsuki Ikoma, Shogo Yamamura, Kou Miura, Takao Tsuduki, Takanori Watanabe, Hiroki Nagai, Masahiro Takatani, Hisateru Yasui

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Toshihiko MatsumotoDepartment of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan. makoharutaro2015@gmail.com.
Tatsuki IkomaDepartment of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan.
Shogo YamamuraDepartment of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan.
Kou MiuraDepartment of Internal Medicine, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan.
Takao TsudukiDepartment of Internal Medicine, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan.
Takanori WatanabeDepartment of Surgery, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan.
Hiroki NagaiDepartment of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan.
Masahiro TakataniDepartment of Internal Medicine, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan.
Hisateru YasuiDepartment of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37488181
PMCPMC10366119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.